Oakrum Pharma, LLC (“Oakrum”), in collaboration with SunGen Pharma, LLC (“SunGen”), announced the U.S. launch and commercial shipment of a generic version of Medrol® (Methylprednisolone) in 4 mg tablets.
It is anticipated that the product will serve the retail market with annual sales in the U.S. exceeding $110 million in the aggregate for the 12-month period ending December 31, 2018 according to available data from IQVIA.
Marco Polizzi, CEO of Oakrum, stated, “We continue to build our product pipeline and grow our partnership network with the addition of SunGen as a proven R&D development partner.” The addition of this product will add to Oakrum’s product portfolio, bringing its total to eight.
Jim Huang, Ph.D., Co-CEO of SunGen, stated, “We are pleased to partner with the Oakrum for this launch. SunGen continues to expand its product development portfolio and has secured eight ANDA approvals and has an additional seven filed with the FDA.”
Isaac Liu, Ph.D., Co-CEO of SunGen, stated, “We are proud to add Methylprednisolone to our growing portfolio of specialty products, as well as announce our sixth product launch. The launch of Methylprednisolone tablet demonstrates our strong development and partnership capabilities. We look forward to collaborating further to bring specialty pharmaceutical drugs to the markets around the world.”
About Oakrum Pharma, LLC
Oakrum Pharma, LLC is a privately-owned biopharmaceutical company focusing on development and commercialization of affordable drug therapies. For more information, visit www.oakrumpharma.com.
About SunGen Pharma LLC
SunGen Pharma, LLC is a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished products. SunGen specializes in the development of oral solid extended release and complex injectable products. SunGen has business partnerships with many US-based generic pharmaceutical companies to develop, manufacture, and sell several pharmaceutical products in the US.
